Uploaded September 2019 | Updated September 2026, 3 weeks ago
Koen Kas is a healthcare futurist, entrepreneur, professor of molecular oncology, acclaimed international keynote speaker, and author of Sick No More and Your Guide to Delight.
He is founding CEO of HealthSkouts and partner at HealthStartup.eu, a social network of novel health start-ups. His team combines real world data, collected via biomarker and sensor measurements, with design and business model innovations into novel, delightful experiences redefining health, helping shape a new breed of digital health companies.
Kas is a professor of oncology at Ghent University in Belgium, and chairs the scientific committee of the European Cancer Prevention Organization. He is an ambassador for Health House. He serves on the advisory board of seven pioneering healthcare companies and a digital health investor. He is a juror of the Prix Galien. He is an editor of the mHealth journal and the European Journal of Cancer Prevention.
Kas was CSO Oncology at Thrombogenics, where he spun out Oncurious, testing a novel drug for pediatric brain cancer. Before this, he was founder and CSO of Pronota, building a protein biomarker discovery platform and pipeline of four diagnostic programs. Prior to that, he was the director of drug discovery at Galapagos. Previously he set up and directed the cancer drug discovery program at Tibotec (now Johnson & Johnson). He started his career elucidating the molecular basis of two types of cancers.
Koen Kas is a healthcare futurist, entrepreneur, professor of molecular oncology, acclaimed international keynote speaker, and author of Sick No More and Your Guide to Delight.
He is founding CEO of HealthSkouts and partner at HealthStartup.eu, a social network of novel health start-ups. His team combines real world data, collected via biomarker and sensor measurements, with design and business model innovations into novel, delightful experiences redefining health, helping shape a new breed of digital health companies.
Kas is a professor of oncology at Ghent University in Belgium, and chairs the scientific committee of the European Cancer Prevention Organization. He is an ambassador for Health House. He serves on the advisory board of seven pioneering healthcare companies and a digital health investor. He is a juror of the Prix Galien. He is an editor of the mHealth journal and the European Journal of Cancer Prevention.
Kas was CSO Oncology at Thrombogenics, where he spun out Oncurious, testing a novel drug for pediatric brain cancer. Before this, he was founder and CSO of Pronota, building a protein biomarker discovery platform and pipeline of four diagnostic programs. Prior to that, he was the director of drug discovery at Galapagos. Previously he set up and directed the cancer drug discovery program at Tibotec (now Johnson & Johnson). He started his career elucidating the molecular basis of two types of cancers.
